Stifel Initiates Coverage On Candel Therapeutics with Buy Rating, Announces Price Target of $22

Benzinga · 2d ago
Stifel analyst Stephen Willey initiates coverage on Candel Therapeutics (NASDAQ:CADL) with a Buy rating and announces Price Target of $22.